Sensorion Stock price

Equities

ALSEN

FR0012596468

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.769 EUR +2.26% Intraday chart for Sensorion -2.04% +78.84%
Sales 2024 * 18.85M 20.35M Sales 2025 * 18.95M 20.45M Capitalization 207M 224M
Net income 2024 * -28M -30.22M Net income 2025 * -40M -43.17M EV / Sales 2024 * 8.29 x
Net cash position 2024 * 51M 55.05M Net cash position 2025 * 5M 5.4M EV / Sales 2025 * 10.7 x
P/E ratio 2024 *
-6.02 x
P/E ratio 2025 *
-4.85 x
Employees 57
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.3%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.59%
1 week-9.55%
Current month-21.98%
1 month-19.32%
3 months+69.25%
6 months+5.03%
Current year+65.12%
More quotes
1 week
0.71
Extreme 0.707
0.85
1 month
0.71
Extreme 0.707
0.98
Current year
0.41
Extreme 0.413
1.04
1 year
0.26
Extreme 0.26
1.04
3 years
0.26
Extreme 0.26
2.67
5 years
0.26
Extreme 0.26
2.88
10 years
0.26
Extreme 0.26
19.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 17-04-11
Chief Tech/Sci/R&D Officer - Dec. 10
Chief Tech/Sci/R&D Officer - 20-02-17
Members of the board TitleAgeSince
Director/Board Member - -
Chairman 59 -
Director/Board Member 59 19-08-31
More insiders
Date Price Change Volume
24-03-28 0.769 +2.26% 89 557
24-03-27 0.752 -7.05% 160,141
24-03-26 0.809 -3.69% 50,595
24-03-25 0.84 0.00% 25,642
24-03-22 0.84 +7.01% 62,008

Real-time Euronext Paris, March 28, 2024 at 07:23 am EDT

More quotes
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.752 EUR
Average target price
2.167 EUR
Spread / Average Target
+188.12%
Consensus
  1. Stock
  2. Equities
  3. Stock Sensorion - Euronext Paris